Navigation Links
Dynogen Reports Positive Results in Phase 1B GERD Study

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 7, 2007 - Dynogen Pharmaceuticals, Inc. reported positive results of its randomized, double-blind, placebo-controlled Phase 1b trial of DDP733 for gastroesophageal reflux disease (GERD). The study was designed to demonstrate proof-of-concept for DDP733 as a treatment for nocturnal GERD (NGERD). The 0.5 mg dose of DDP733 achieved statistical significance over placebo on the primary endpoint of reduction in the number of reflux events and was safe and well tolerated. Dynogen is planning to initiate a Phase 2 study of DDP733 in GERD patients in 2008.

DDP733 is an oral, partial agonist of the serotonin type 3 receptor (5-HT(3)), which Dynogen is developing for gastrointestinal conditions such as GERD and irritable bowel syndrome with constipation (IBS-c). In this translational medicine study, healthy volunteers were given a high fat meal to induce gastroesophageal reflux. Reflux events were measured by intraesophageal impedance (the electrical resistance that provides insight into the height and duration of a reflux episode).

"With this second set of positive proof-of-concept data for DDP733, following closely on the heels of our positive Phase 2 data for DDP733 in irritable bowel syndrome with constipation, we've unlocked the potential of this compound as a treatment for two distinct and underserved GI disorders," said Lee R. Brettman, M.D., Chief Executive Officer at Dynogen. "We estimate the peak sales for these indications to be in excess of a billion dollars each, reflecting the significant unmet medical need represented by these disorders. Dynogen has the opportunity to make a real difference in the quality of life of many patients suffering from these disorders."

"We designed this study with the dual goals of obtaining an indication of efficacy and establishing appropriate doses for our later-stage clinical study, and I am pleased to say we accomplished both
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Dynogens DDP733 Reduces Reflux in Phase 1b GERD Study
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Dynogen Reports Positive Results Phase GERD Study
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® in the ... that BioSpecifics, President, Tom Wegman , will present a ... in the Biotech Industry Conference. The presentation ... p.m. EDT at the Millennium Broadway Hotel in ...
(Date:9/19/2014)... Tenn. , Sept. 19, 2014  Over 200 ... the Future to Benefit the Radiation Oncology Institute (ROI), ... held at Golden Gate Park in San Francisco.  ... Dan Moore , CEO of Radiation Business Solutions, ... we have raised over $70,000 for the ROI this ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Jan. 11 Derycz Scientific (OTC Bulletin Board: DYSC), a company ... information from content publishers to enterprise customers and their constituents, is ... website of DDN ( Drug Discovery News ). The ... titled "Speeding the Path to FDA Approval in the Era of ...
... PARIS, Jan. 11 Sanofi-aventis (EURONEXT: SAN and NYSE: ... its wholly-owned subsidiary, River Acquisition Corp., for all outstanding shares of ... per share, net to the seller in cash, without interest and ... made pursuant to an Offer to Purchase, dated January 11, 2010, ...
Cached Medicine Technology:Derycz Scientific Featured In DDN (Drug Discovery News) 2Derycz Scientific Featured In DDN (Drug Discovery News) 3Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc. 2Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc. 3Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc. 4Sanofi-aventis Commences Tender Offer for All Outstanding Shares of Chattem, Inc. 5
(Date:9/22/2014)... Fancyflyingfox.com, the well-known wedding dress manufacturer and retailer, has recently ... dresses . In addition, the company has also deiced to ... Each item in the new range is now provided with ... The company has thousands of unique special occasion outfits for ... affordable prices. Its products are brand new and made with ...
(Date:9/21/2014)... the birth of an infant prior to 37 ... that has increased over the past two decades. ... (CDC), preterm birth affects nearly 500,000 babies each year, ... While medical care has improved survival rates for preterm ... neurodevelopmental outcomes of preterm infants. , Research led by ...
(Date:9/21/2014)... UNIWIGS, one of the leading online stores of real ... a line of human hair lace wigs inspired by 6 ... people what the latest celebrity hairstyles are. , ... 4 different hairstyles to choose from: a style of yaki ... and a hot ombre red lace wig. People can go ...
(Date:9/21/2014)... authorities focus on the physical activity benefits of active ... reveals that for children, playing has no goal ... is fun, done alone or with friends, and it ... also to combat boredom, sadness, fear, or loneliness." "By ... put aside several aspects of play that are beneficial ...
(Date:9/21/2014)... peanuts are more likely to trigger an allergy to ... involving mice. , The researchers say that specific chemical ... roasting process are recognised by the body,s immune system, ... response the next time it sees any peanuts. , ... of people with peanut allergies in the Western world ...
Breaking Medicine News(10 mins):Health News:Discounted Plus Size Wedding Dresses Available At Fancyflyingfox.com 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Narrow focus on physical activity could be ruining kids' playtime 2Health News:Dry roasting could help trigger peanut allergy 2
... ... brought another family together for the holidays , ... (PRWEB) December 31, 2009 -- Celebrating the holidays under the grip of ... story evoking the true spirit of the holidays. "Before he began using drugs like ...
... ... year right , ... (PRWEB) -- Massage Envy , the nation’s largest massage therapy provider, recommends ringing in ... program. Along with resolving to eat healthier, take vitamins and exercise more frequently, incorporating ...
... a little extra incentive to kick the habit? Just ... that even after age 80, smoking continues to increase one,s ... blindness in Americans over 65. The ... January edition. "The take-home message is that it,s never ...
... , GAINESVILLE, Fla., ... the delegation at the Florida House on Capitol Hill in Washington, ... efforts to establish a gallery and learning center in Ft. Myers, ... while bridging differences and strengthening relationships. , (Photo: ...
... of the Streptococcus pneumoniae in samples that ... may predict risk of severe disease in H1N1 pandemic ... associated with higher morbidity and mortality than in other ... Immunity (CII) at the Mailman School of Public Health ...
... , , , , WOONSOCKET, ... will provide H1N1 flu vaccinations at select CVS/pharmacy ... and New York as well at MinuteClinic locations in Massachusetts ... ) , Public health officials are now encouraging everyone ...
Cached Medicine News:Health News:Mother and Son Spend Holidays Free of Drug Addiction 2Health News:Ring in a Healthy New Year with Massage Therapy in 2010 2Health News:It's never too late to quit smoking and save your vision 2Health News:Founders of the Sebastian Ferrero Foundation Join HSH Prince Albert II of Monaco in Support of the New Art of the Olympians Museum 2Health News:Founders of the Sebastian Ferrero Foundation Join HSH Prince Albert II of Monaco in Support of the New Art of the Olympians Museum 3Health News:Founders of the Sebastian Ferrero Foundation Join HSH Prince Albert II of Monaco in Support of the New Art of the Olympians Museum 4Health News:Severity of H1N1 influenza linked to presence of Streptococcus pneumoniae 2Health News:CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccines in 8 New States 2Health News:CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccines in 8 New States 3Health News:CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccines in 8 New States 4
... closes various plastic primary and secondary tubes in ... heights and diameters can be sealed in one ... send-outs. The integration into other PVT Systems (e.g. ... and High Throughput Sorter RSD ProVolume ) ...
... MGB Alert Detection Reagents provide molecular ... PCR based assays. By using our MGB ... analysis, Nanogen is now able to provide ... nucleic acid sequences of specific organisms or ...
... for the detection of two genetic ... mutation on the Factor V (Leiden) ... the Prothrombin gene. Laboratories may use ... *Analyte Specific Reagents. Analytical ...
... the latest and most advanced fecal occult ... line. An immunochemical FOBT (iFOBT) with high ... proven to detect bleeding associated with more ... Because of its superior specificity for lower ...
Medicine Products: